A compound of Formula I: ** Formula ** or pharmaceutically acceptable salt thereof or prodrug thereof, in which: A is N； Cy1 is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4, or 5-W-X-Y-Z-； Cy2 is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4, or 5-W'-X'-Y'-Z '； L1 is (CR4R5) m； L2 is (CR7R8) r, (CR7R8) s- (cycloalkylene) - (CR7R8) t, (CR7R8) s- (arylene) - (CR7R8) t, (CR7R8) s- (heterocycloalkylene) - (CR7R8) t, ( CR7R8) s- (heteroarylene) - (CR7R8) t, (CR7R8) sO (CR7R8) t, (CR7R8) sS (CR7R8) t, (CR7R8) sC (O) (CR7R8) t, (CR7R8) sC (O) NR9 (CR7R8) t, (CR7R8) sC (O) O (CR7R8) t, (CR7R8) sOC (O) (CR7R8) t, (CR7R8) sOC (O) NR9 (CR7R8) t, (CR7R8) sNR9 (CR7R8 ) t, (CR7R8) sNR9C (O) NR9 (CR7R8) t, (CR7R8) sS (O) (CR7R8) t, (CR7R8) sS (O) NR7 (CR8R9) t, (CR7R8) sS (O) 2 ( CR7R8) t, or (CR7R8) sS (O) 2NR9 (CR7R8) t, wherein said cycloalkylene, arylene, heterocycloalkylene, or heteroarylene is optionally substituted by 1, 2, or 3 substituents independently selected from Cy4, halo, C1-6 alkyl , C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halosulfanyl, CN, NO2, N3, ORa1, SRa1, C (O) Rb1, C (O) NRc1Rd1, C (O) ORa1, OC (O) Rb1, OC (O) NRc1Rd1, NRc1Rd1, NRc1C (O) Rb1, NRc1C (O) NRc1Rd1, NRc1C (O) ORa1, C (>； = NRg) NRc1Rd1, NRc1C (>； = NRg) NRc1 Rd1 P (Rf1) 2, P (ORc1) 2, P (O) Rc1Rf1, P (O) ORc1ORf1, S (O) Rb1, S (O) NRc1Rd1, S (O) 2Rb1, NRc1S (O) 2Rb1, and S (O) 2NRc1Rd1 ； R1 is H or -W "-X" -Y "-Z"； R2 is H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl,, CN, NO2, ORA, SRA, C (O) RB, C (O) NRCRD, C (O ) ORA, OC (O) RB, OC (O) NRCRD, NRCRD, NRCC (O) RB, NRCC (O) NRCRD, NRCC (O) ORA, S (O) RB, S (O) NRCRD, S (O ) 2RB, NRCS (O) 2RB, or S (O) 2NRCRD； or R2 and -L2-Cy2 are linked together to form a group of formula: ** Formula ** where ring B is a fused aryl or fused heteroaryl ring, each optionally substituted by 1, 2, or 3 -W ' -X AND Z'； R4 is H； R5 is selected from
